Enovis (NYSE:ENOV) Price Target Raised to $42.00

Enovis (NYSE:ENOV) had its price objective boosted by stock analysts at Wells Fargo & Company from $41.00 to $42.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 49.92% from the company’s previous close.

ENOV has been the subject of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a report on Wednesday, October 8th. Needham & Company LLC reduced their price objective on shares of Enovis from $57.00 to $49.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Canaccord Genuity Group lowered their target price on shares of Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, UBS Group dropped their target price on shares of Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Enovis presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.17.

Enovis Stock Down 1.4%

NYSE:ENOV traded down $0.41 during trading hours on Friday, reaching $28.02. The company’s stock had a trading volume of 1,092,886 shares, compared to its average volume of 1,104,868. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -1.97 and a beta of 1.67. Enovis has a one year low of $25.47 and a one year high of $49.75. The business’s 50-day moving average is $31.39 and its 200-day moving average is $31.50.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Monday, January 8th. The company reported $0.59 earnings per share for the quarter. The company had revenue of $383.81 million during the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%. Equities research analysts predict that Enovis will post 2.79 EPS for the current year.

Insider Buying and Selling

In other news, CEO Damien Mcdonald bought 6,457 shares of the firm’s stock in a transaction that occurred on Thursday, September 11th. The shares were acquired at an average cost of $30.97 per share, with a total value of $199,973.29. Following the completion of the transaction, the chief executive officer directly owned 102,753 shares in the company, valued at $3,182,260.41. This represents a 6.71% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Phillip Benjamin (Ben) Berry purchased 2,500 shares of the business’s stock in a transaction on Wednesday, August 20th. The stock was purchased at an average cost of $29.71 per share, with a total value of $74,275.00. Following the acquisition, the chief financial officer owned 116,729 shares in the company, valued at approximately $3,468,018.59. This represents a 2.19% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 12,157 shares of company stock valued at $374,760 over the last three months. 2.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enovis

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Enovis by 11.3% in the 1st quarter. Vanguard Group Inc. now owns 6,107,199 shares of the company’s stock valued at $233,356,000 after buying an additional 621,069 shares during the period. Tributary Capital Management LLC boosted its position in shares of Enovis by 91.5% during the 3rd quarter. Tributary Capital Management LLC now owns 1,154,482 shares of the company’s stock valued at $35,027,000 after acquiring an additional 551,613 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Enovis by 191.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 810,771 shares of the company’s stock valued at $26,772,000 after acquiring an additional 532,648 shares during the period. AQR Capital Management LLC raised its position in Enovis by 682.6% in the second quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock worth $15,627,000 after purchasing an additional 434,646 shares in the last quarter. Finally, Boston Partners raised its position in Enovis by 42.4% in the second quarter. Boston Partners now owns 1,382,724 shares of the company’s stock worth $43,352,000 after purchasing an additional 411,744 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.